115 related articles for article (PubMed ID: 35485332)
1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults.
Gane E; Pastagia M; Schwertschlag U; De Creus A; Schwabe C; Vandenbossche J; Slaets L; Fevery B; Smyej I; Wu LS; Li R; Siddiqui S; Oey A; Musto C; Van Remoortere P
Antivir Ther; 2021 May; 26(3-5):58-68. PubMed ID: 35485332
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants.
Wu LS; Hu Y; Gane EJ; Slaets L; De Creus A; Ding Y; Niu J; Schwabe C; Goeyvaerts N; Xu Z; Huo D; Tuefferd M; Verbrugge I; Van Remoortere P; Schwertschlag U; Vandenbossche J
Antivir Ther; 2023 Feb; 28(1):13596535231151626. PubMed ID: 36691849
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers.
Kakuda TN; Yogaratnam JZ; Westland C; Gane EJ; Schwabe C; Vuong J; Patel M; Snoeys J; Talloen W; Lenz O; Fry J; Chanda S; van Remoortere P
Antivir Ther; 2021; 26(1-2):13-24. PubMed ID: 35485346
[TBL] [Abstract][Full Text] [Related]
4. First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MHV370, a Dual Inhibitor of Toll-Like Receptors 7 and 8, in Healthy Adults.
Shisha T; Posch MG; Lehmann J; Feifel R; Junt T; Hawtin S; Schuemann J; Avrameas A; Danekula R; Misiolek P; Siegel R; Gergely P
Eur J Drug Metab Pharmacokinet; 2023 Sep; 48(5):553-566. PubMed ID: 37532923
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase.
Leu JH; Miao X; Shalayda K; Coe KJ; Kahnt A; Wu B; Schnarr M; Franks C; Devlin J; Yang TY; Palmer JA; Zhang M; Zhou H; Van Damme W; Smets S; Aguilar Z; Chaplan SR
Clin Pharmacol Drug Dev; 2023 Jun; 12(6):611-624. PubMed ID: 37125450
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
Yao Z; Loggia L; Fink D; Chevrier M; Marciniak S; Sharma A; Xu Z
Clin Drug Investig; 2020 Dec; 40(12):1127-1136. PubMed ID: 33085033
[TBL] [Abstract][Full Text] [Related]
8. Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Learnings from a Double-Blind, Randomized, Placebo-Controlled, Sequential Group First-in-Human Study of the TRPV1 Antagonist, JNJ-38893777, in Healthy Men.
Manitpisitkul P; Mayorga A; Shalayda K; De Meulder M; Romano G; Jun C; Moyer JA
Clin Drug Investig; 2015 Jun; 35(6):353-63. PubMed ID: 25894894
[TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers.
Ackaert O; Vanhoutte F; Verpoorten N; Buelens A; Lachau-Durand S; Lammens L; Hoetelmans R; Van Loock M; Herrera-Taracena G
Clin Infect Dis; 2023 Sep; 77(6):857-865. PubMed ID: 37161721
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.
Vandenbossche J; Jessner W; van den Boer M; Biewenga J; Berke JM; Talloen W; De Zwart L; Snoeys J; Yogaratnam J
Adv Ther; 2019 Sep; 36(9):2450-2462. PubMed ID: 31267367
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.
Wu J; Zhou R; Zhang Q; Zhang Q; Qin H; Ye Z; Xu Y; Feng S; Shu C; Shen Y; Fan Y; Wang Q; Du Y; Hu W
Diabetes Obes Metab; 2024 Mar; 26(3):901-910. PubMed ID: 38100147
[TBL] [Abstract][Full Text] [Related]
12. A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep).
Manitpisitkul P; Flores CM; Moyer JA; Romano G; Shalayda K; Tatikola K; Hutchison JS; Mayorga AJ
Scand J Pain; 2018 Apr; 18(2):151-164. PubMed ID: 29794306
[TBL] [Abstract][Full Text] [Related]
13. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.
Gane E; Yuen MF; Kakuda TN; Ogawa T; Takahashi Y; Goeyvaerts N; Lonjon-Domanec I; Vaughan T; Schluep T; Hamilton J; Njumbe Ediage E; Hillewaert V; Snoeys J; Lenz O; Talloen W; Biermer M
Antivir Ther; 2022 Jun; 27(3):13596535221093856. PubMed ID: 35695169
[TBL] [Abstract][Full Text] [Related]
14. A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers.
Luk A; Jiang Q; Glavini K; Triyatni M; Zhao N; Racek T; Zhu Y; Grippo JF
Clin Transl Sci; 2020 Sep; 13(5):985-993. PubMed ID: 32268000
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
Lawitz E; Gruener D; Marbury T; Hill J; Webster L; Hassman D; Nguyen AH; Pflanz S; Mogalian E; Gaggar A; Massetto B; Subramanian GM; McHutchison JG; Jacobson IM; Freilich B; Rodriguez-Torres M
Antivir Ther; 2015; 20(7):699-708. PubMed ID: 25105516
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects.
Akpalu DE; Frederick B; Nnane IP; Yao Z; Shen F; Ort T; Fink D; Dogmanits S; Raible D; Sharma A; Xu Z
J Clin Pharmacol; 2019 Jul; 59(7):968-978. PubMed ID: 30776134
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants.
Li H; Niu X; Zhang Y; Zhang D; Zhang Y; Wang L; Miao Y; Jiang Y; Ji J; Chen Q; Wu X; Ediage EN; Kakuda TN; Biermer M
Clin Pharmacol Drug Dev; 2023 Feb; 12(2):175-180. PubMed ID: 36415122
[TBL] [Abstract][Full Text] [Related]
18. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects.
van der Ark PD; Golor G; van Nueten L; Nandy P; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1330-1340. PubMed ID: 30182786
[TBL] [Abstract][Full Text] [Related]
19. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.
Zoulim F; Lenz O; Vandenbossche JJ; Talloen W; Verbinnen T; Moscalu I; Streinu-Cercel A; Bourgeois S; Buti M; Crespo J; Manuel Pascasio J; Sarrazin C; Vanwolleghem T; Shukla U; Fry J; Yogaratnam JZ
Gastroenterology; 2020 Aug; 159(2):521-533.e9. PubMed ID: 32343960
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study.
Martinón-Torres F; Rusch S; Huntjens D; Remmerie B; Vingerhoets J; McFadyen K; Ferrero F; Baraldi E; Rojo P; Epalza C; Stevens M
Clin Infect Dis; 2020 Dec; 71(10):e594-e603. PubMed ID: 32201897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
